| Name | Title | Contact Details |
|---|
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.
Dzeel Clinical is a Garner, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OmniAb is a leading edge antibody discovery company that provides access to diverse antibody repertoires and high throughput screening technologies. They specialize in therapeutic antibody discovery using chickens as immunization hosts, which allows fo...
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.